Xeris Biopharma Holdings (LTS:0A8E) Other Net Income (Loss) : $-0.0 Mil (TTM As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Xeris Biopharma Holdings Other Net Income (Loss)?

Xeris Biopharma Holdings's Other Net Income (Loss) for the three months ended in Sep. 2024 was $0.0 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.0 Mil.

Xeris Biopharma Holdings's quarterly Other Net Income (Loss) increased from Mar. 2024 ($-0.0 Mil) to Jun. 2024 ($0.0 Mil) and increased from Jun. 2024 ($0.0 Mil) to Sep. 2024 ($0.0 Mil).

Xeris Biopharma Holdings's annual Other Net Income (Loss) stayed the same from Dec. 2021 ($0.0 Mil) to Dec. 2022 ($0.0 Mil) but then declined from Dec. 2022 ($0.0 Mil) to Dec. 2023 ($-0.0 Mil).

Xeris Biopharma Holdings Other Net Income (Loss) Historical Data

The historical data trend for Xeris Biopharma Holdings's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xeris Biopharma Holdings Other Net Income (Loss) Chart

Xeris Biopharma Holdings Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Net Income (Loss)

Get a 7-Day Free Trial

Xeris Biopharma Holdings Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Other Net Income (Loss)	Get a 7-Day Free Trial															-	-	-	-	-

Xeris Biopharma Holdings Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.0 Mil.

Xeris Biopharma Holdings Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Xeris Biopharma Holdings's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Xeris Biopharma Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xeris Biopharma Holdings Inc (LTS:0A8E) » Definitions » Other Net Income (Loss)

Comparable Companies

Traded in Other Exchanges

XERS:USA 2B30:Germany

Address

1375 West Fulton Street, Suite 1300, Chicago, IL, USA, 60607

Website

https://www.xerispharma.com

Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.

Xeris Biopharma Holdings Headlines

No Headlines